Princeton, NJ, September 5, 2023 ─ iQure Pharma Inc. (iQure), a company dedicated to the development of new epilepsy and pain management therapeutics, is proud to announce that its lead asset, iQ-007, has been accepted into the prestigious NIH PSPP (part of the NIH HEAL Initiative) program to identify and profile non-addictive therapeutics for pain.
iQ-007 is a positive allosteric modulator of the EAAT2 transporter and represents a novel approach to treat neurodegenerative diseases. iQ-007 showed efficacy in pain models and has successfully completed the NIH ETSP (Epilepsy Therapy Screening Program) , which focuses on new therapies for drug resistant epilepsy. The acceptance of iQ-007 into the PSPP program is another confirmation of the importance of glutamate management in neurodegenerative diseases and the role iQ-007 can play in the treatment of different indications. “With its excellent profile in epilepsy, we are confident that iQ-007 can also play an important role in the treatment of neuropathic pain. Experimental results from the NIH PSPP program will add to the existing data and contribute significantly to iQ-007’s profile for alleviating neuropathic pain.” said Chief Executive Officer, Pawel Zolnierczyk,
The PSPP program provides a fully NIH-funded, stepwise testing approach, including an assessment of in vitro binding studies and pharmacokinetic profiles, side effect profiles, abuse liability, and efficacy in models relevant to human pain conditions.
About iQure Pharma
iQure Pharma, a global biotech firm headquartered in the US, is focused on the development of new therapeutics for CNS, including neuropathic pain, epilepsy and other neurodegenerative diseases. iQure researchers, clinicians, and pharmaceutical professionals work closely with academic partners, industry experts, and patient organizations to build medically and socially beneficial therapies. For more information about supporting iQure’s initiatives, contact iQure CEO Pawel Zolnierczyk at firstname.lastname@example.org.